Chronic paraneoplastic cutaneous syndrome preceding an indolent variant of mantle cell lymphoma: favorable response to rituximab.
Mantle cell lymphoma (MCL) is an aggressive type of malignant lymphoma with short median survival despite conventional therapy. We describe the unusual case of a 66-year-old man with a chronic skin rash which preceded the occurrence of an indolent MCL by 2 years. Repeated skin biopsies did not show involvement by the lymphoma. Short therapy with rituximab resulted in the complete and lasting resolution of the cutaneous lesions.
Nemets
Anatoly
A
J. Michaeli Department of Hematology, Barzilai Medical Center, Ashkelon, Israel. nemets@barzi.health.gov.il
Ronen
Meir
M
Lugassy
Gilles
G
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000150:complications / Q000188:drug therapy*; D008297:Male; D016609:Neoplasms, Second Primary / Q000150:complications / Q000188:drug therapy*; D010257:Paraneoplastic Syndromes / Q000150:complications / Q000188:drug therapy*; D000069283:Rituximab; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab